Report of Foreign Issuer (6-k)
July 17 2017 - 7:06AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of July 2017
001-36203
(Commission
File Number)
CAN-FITE
BIOPHARMA LTD.
(Exact
name of Registrant as specified in its charter)
10
Bareket Street
KiryatMatalon,
P.O. Box 7537
Petach-Tikva
4951778, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover
Form 20-F
or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T
Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T
Rule 101(b)(7): ____
The
first paragraph and “Forward Looking Statements” of the press release attached to this Form 6-K are hereby incorporated
by reference into the registrant's Registration Statements on Form F-3 (File Nos. 333-195124, 333-199033, 333-204795 and 333-209037),
to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.
On
July 17, 2017, Can-Fite BioPharma Ltd. (the “Company”) issued a press release announcing that it successfully concluded
a Clinical Investigator Meeting with the principal investigators, researchers, and doctors participating as clinical investigators
in the Company’s Phase II trial of its drug candidate Namodenoson in the treatment of non-alcoholic fatty liver disease
(NAFLD) and non-alcoholic steatohepatitis (NASH). A copy of this press release is attached hereto as Exhibit
99.1 and is incorporated herein by reference.
Exhibit
Index
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Can-Fite
BioPharma Ltd.
|
|
|
|
Date:
July 17, 2017
|
By:
|
/s/
Pnina Fishman
|
|
|
Pnina
Fishman
|
|
|
Chief
Executive Officer
|
4
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Sep 2023 to Sep 2024